Jaguar Health (JAGX) Total Non-Current Liabilities (2014 - 2026)
Jaguar Health (JAGX) reported Total Non-Current Liabilities of $53.0 million for Q1 2026, up 375.84% year-over-year from $11.1 million in Q1 2025, and up 111.07% quarter-over-quarter from $25.1 million in Q4 2025.
Jaguar Health (JAGX) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 13 years of Total Non-Current Liabilities data on file, last reported at $53.0 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $53.0 million, up 375.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $53.0 million (up 375.84% YoY), and the FY2025 annual result was $25.1 million, up 176.24% from the prior year.
- Total Non-Current Liabilities grew to $53.0 million in Q1 2026 per JAGX's latest filing, from $25.1 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $53.0 million in Q1 2026 and troughed at $9.1 million in Q4 2024.
- A 5-year average of $22.3 million and a median of $14.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities tumbled 63.57% in 2023, then soared 375.84% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $41.0 million in 2022, then plunged by 63.57% to $14.9 million in 2023, then sank by 39.09% to $9.1 million in 2024, then soared by 176.24% to $25.1 million in 2025, then surged by 111.07% to $53.0 million in 2026.
- Business Quant data shows JAGX's Total Non-Current Liabilities at $53.0 million in Q1 2026, $25.1 million in Q4 2025, and $14.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 42,980.09 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 64.76 Mn |
| 10 | Jaguar Health | 1.44 Mn | -10.19 Mn | 19.11 Mn | 53.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.00 Mn |
| Dec 31, 2025 | 25.11 Mn |
| Sep 30, 2025 | 14.69 Mn |
| Jun 30, 2025 | 12.58 Mn |
| Mar 31, 2025 | 11.14 Mn |
| Dec 31, 2024 | 9.09 Mn |
| Sep 30, 2024 | 10.09 Mn |
| Mar 31, 2024 | 9.13 Mn |
| Dec 31, 2023 | 14.92 Mn |
| Dec 31, 2022 | 40.97 Mn |
| Mar 31, 2022 | 44.80 Mn |
| Dec 31, 2021 | 41.41 Mn |
| Sep 30, 2021 | 37.70 Mn |
| Jun 30, 2021 | 37.75 Mn |
| Mar 31, 2021 | 36.81 Mn |
| Dec 31, 2020 | 25.64 Mn |
| Sep 30, 2020 | 28.30 Mn |
| Jun 30, 2020 | 21.07 Mn |
| Mar 31, 2020 | 15.42 Mn |
| Dec 31, 2019 | 14.34 Mn |